MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Celator Pharmaceuticals Company Profile (NASDAQ:CPXX)

Consensus Ratings for Celator Pharmaceuticals (NASDAQ:CPXX) (?)
Ratings Breakdown: 4 Hold Rating(s), 3 Buy Rating(s)
Consensus Rating:Hold (Score: 2.43)
Consensus Price Target: $18.67 (38.17% downside)

Analysts' Ratings History for Celator Pharmaceuticals (NASDAQ:CPXX)
Show:
DateFirmActionRatingPrice TargetActions
6/1/2016Janney Montgomery ScottDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Stifel NicolausDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Needham & Company LLCDowngradeBuy -> HoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/31/2016Roth CapitalDowngradeBuy -> Neutral$30.25 -> $26.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/15/2016HC WainwrightBoost Price TargetBuy$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2015FBR & Co.Reiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/12/2015MLV & Co.Reiterated RatingBuy$6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/24/2014 forward)
Earnings History for Celator Pharmaceuticals (NASDAQ:CPXX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/10/2016Q116($0.15)($0.16)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/21/2016Q4($0.12)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2015Q315($0.16)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.14)($0.15)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015($0.14)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/17/2015($0.16)($0.07)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/13/2014($0.21)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014($0.20)($0.18)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2014($0.24)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/24/2014Q4 13($0.15)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2013($0.20)($0.14)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Celator Pharmaceuticals (NASDAQ:CPXX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.15)($0.15)($0.15)
Q2 20162($0.15)($0.14)($0.15)
Q3 20162($0.16)($0.14)($0.15)
Q4 20162($0.18)($0.13)($0.16)
(Data provided by Zacks Investment Research)
Dividend History for Celator Pharmaceuticals (NASDAQ:CPXX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Celator Pharmaceuticals (NASDAQ:CPXX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
12/3/2015Scott D MorensteinDirectorBuy5,000$1.87$9,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/6/2015Scott Thomas JacksonCEOBuy14,450$1.74$25,143.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/5/2015Fred M PowellCFOBuy13,700$1.78$24,386.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Life Sciences Gp Ll Valence IIinsiderBuy12,200$1.64$20,008.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Fred M PowellCFOBuy6,000$2.20$13,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Michael R DoughertyDirectorBuy20,000$2.15$43,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/18/2014Scott Thomas JacksonCEOBuy10,000$2.20$22,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Fred M PowellCFOBuy2,500$2.50$6,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Fred M PowellCFOBuy2,500$3.50$8,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Scott Thomas JacksonCEOBuy3,000$3.50$10,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Celator Pharmaceuticals (NASDAQ:CPXX)
DateHeadline
06/24/16 03:31 PMShares Reaching Overbought Territory: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) - Press Telegraph
06/24/16 03:31 PMPrice Target Update on Celator Pharmaceuticals (NASDAQ:CPXX) - Trade Calls
06/23/16 02:48 PMCelator Pharmaceuticals Inc. (CPXX) Current Analyst Ratings - Fiscal Standard
06/23/16 02:48 PMCelator Pharmaceuticals Inc. (CPXX) Updated Price Targets - FTSE News
06/22/16 08:30 AMSlingshot Insights Hosts Informative Call On Moleculin Biotech: Here Are The Details - Slingshot Insights, a crowdfunded expert network that offers investment research tools, conducted an expert call on Moleculin Biotech Inc (NASDAQ: MBRX) AML drug Annamycin last Friday. The goal of the call was to offer investors the opportunity to better understand how the drug differs from competing drugs, such as Celator Pharmaceuticals Inc (NASDAQ: CPXX)'s VYXEOS. Slingshot Insights' expert on the call was medical oncologist and professor at Johns Hopkins University Dr. Gabriel Ghiaur. The doctor is also a double board certified in Hematology and Internet Medicine, with numerous publications ...Full story available on Benzinga.com
06/20/16 03:20 PMCelator Pharmaceuticals Inc. (CPXX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/17/16 03:14 PMMost Recent Update on Price Moves: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , Acadia Healthcare Company ... - Street Updates
06/15/16 08:07 AMStock's Price Moves: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) , Celator Pharmaceuticals Inc. (NASDAQ:CPXX) - Street Updates
06/15/16 08:07 AMCutting Edge Stocks in Focus- Celator Pharmaceuticals (NASDAQ:CPXX), Telefonaktiebolaget LM Ericsson (NASDAQ ... - Seneca Globe
06/14/16 09:09 PMYale Joins PTX’s Phase 1b/2 AML Clinical Trial - [at noodls] - 5535e098-6096-474f-b2ed-3925471117d7.pdf ASX Release Yale Joins PTX's Phase 1b/2 AML Clinical Trial Melbourne, Australia - (15 June, 2016) - Clinical-stage oncology company Prescient Therapeutics Limited ...
06/14/16 03:16 PMHC Stocks Reports: Celator Pharmaceuticals Inc (NASDAQ:CPXX), Geron Corporation (NASDAQ:GERN) - share market updates (press release)
06/14/16 03:16 PMStocks Earnings Analysis Report: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX), Digital Realty Trust Inc. (NYSE:DLR) - Beacon Chronicle
06/14/16 07:41 AMCompany Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Announces Positive Results in Patients with FLT3 ... - Smarter Analyst
06/13/16 02:49 PMAnalyst Overview on these Stocks: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX), Uranium Energy Corp. (NYSEMKT ... - Beacon Chronicle
06/11/16 03:28 PMAnalysts Rating Alert: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , Jaguar Animal Health, Inc. (NASDAQ:JAGX) - Street Updates
06/08/16 05:36 PMSHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of The Board of Directors of Celator Pharmaceuticals, Inc. - CPXX - [Accesswire] - BALA CYNWYD, PA / ACCESSWIRE / June 8, 2016 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc. ("Celator" ...
06/07/16 03:28 PMStock under Analyst' Radar: Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) - News Oracle
06/07/16 11:42 AMStocks within Traders Radar: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , CytRx Corporation (NASDAQ:CYTR) - Street Updates
06/07/16 11:42 AMRoth Capital Downgrades Celator Pharmaceuticals Inc to Neutral with Price Target $30.25 - Trade Calls
06/06/16 04:13 PMCELATOR PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits -
06/06/16 03:14 PMCelator Pharmaceuticals (CPXX) Presents Positive VYXEOS Phase 3 Data at ASCO; Strong OS Results Noted - StreetInsider.com
06/06/16 06:01 AM7:01 am Celator Pharma presents phase 3 trial results in patients with high-risk acute myeloid leukemia demonstrating Vyxeos 'significantly improved' overall survival -
06/06/16 06:00 AMCelator Pharmaceuticals® Presented Phase 3 Trial Results in Patients with High-Risk Acute Myeloid Leukemia Demonstrating VYXEOS™ (CPX-351) Significantly Improved Overall Survival - [PR Newswire] - EWING, N.J., June 6, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (CPXX) today announced results from its Phase 3 trial of VYXEOS™ (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with high-risk (secondary) acute myeloid leukemia (AML) were presented at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting. The median overall survival for patients treated with VYXEOS in the study was 9.56 months compared to 5.95 months for patients receiving 7+3, representing a 3.61 month improvement in favor of VYXEOS. Event-free survival was also statistically significant in favor of VYXEOS.
06/04/16 08:40 AMWhy Celator Pharmaceuticals Shares Skyrocketed 100% in May -
06/03/16 09:31 PMCelator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders - PR Newswire (press release)
06/03/16 05:21 PMCelator Pharmaceuticals, Inc. Acquisition May Not Be in the Best Interests of CPXX Shareholders - [PR Newswire] - NEW YORK, June 3, 2016 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Celator Pharmaceuticals, Inc. ("CPXX" or the "Company") in connection with the proposed acquisition of the Company by Jazz Pharmaceuticals plc ("Jazz"). On May 31, 2016, the Company announced it had reached a definitive agreement for Jazz to acquire all outstanding shares of CPXX pursuant to a tender offer for $30.25 in cash for each share of Company common stock. WeissLaw is investigating whether CPXX's Board acted to maximize shareholder value prior to entering into the agreement. Notably, the Company recently announced its financial results for the first quarter of 2016. CPXX reported having cash and cash equivalents of $67.5 million, compared to $23.3 million as of December 31, 2015. CPXX Chief Executive Officer Scott Jackson stated the "first quarter of 2016 was transformative for Celator." Additionally, certain CPXX shareholders, including the Company's executive officers and Board members, have agreed to tender their shares in the transaction.
06/03/16 11:40 AMAnalysts' Activity: Celator Pharmaceuticals Inc (NASDAQ:CPXX) - The Point Review
06/03/16 08:46 AMThe market is looking for a Celator spoiler bid -
06/02/16 03:29 PMCelator Pharmaceuticals Inc. (NASDAQ:CPXX) Quarterly EPS Estimate At $-0.170 - Investor Newswire - Celator Pharmaceuticals Inc. (NASDAQ:CPXX) Quarterly EPS Estimate At $-0.170Investor NewswireFirst Call stated that Celator Pharmaceuticals Inc. (NASDAQ:CPXX) can touch $26.750 in coming one year. For the next quarter, the per-share earnings target is $-0.170 and for ongoing fiscal at $-0.620. EPS target for next year is $-0.050 versus the ...and more »
06/02/16 12:21 PMCELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Jazz Pharmaceuticals plc - [Business Wire] - Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor LLP are investigating potential claims against the Board of Directors of Celator Pharmaceuticals, Inc.
06/02/16 11:11 AMAnalyst Ratings on: Shire plc (NASDAQ:SHPG), Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) - Beacon Chronicle - Beacon ChronicleAnalyst Ratings on: Shire plc (NASDAQ:SHPG), Celator Pharmaceuticals, Inc. (NASDAQ:CPXX)Beacon ChronicleLast Trade: The Company closed its last session at $191.23 with the gain of 2.72%. The market capitalization of the company is $37.75 Billion, with the average Volume of 2.75 Million. The stock currently has its 52-Week High range of $270.63 and 52 ...and more »
06/02/16 11:10 AMNotable HC Stocks Preview: Celator Pharmaceuticals Inc (NASDAQ:CPXX), Allergan plc Ordinary Shares (NYSE:AGN) - share market updates (press release) - Notable HC Stocks Preview: Celator Pharmaceuticals Inc (NASDAQ:CPXX), Allergan plc Ordinary Shares (NYSE:AGN)share market updates (press release)Shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX) ended Wednesday session in green amid volatile trading. The shares closed up +0.12 points or 0.40% at $30.20 with 5.45 million shares getting traded. Post opening the session at $30.00, the shares ...and more »
06/01/16 09:31 PMCelator Pharmaceuticals, Inc. (NASDAQ:CPXX) Jumped 71.59%: Westar Energy, Inc. (NYSE:WR), Medtronic plc ... - KC Register - MyAJCCelator Pharmaceuticals, Inc. (NASDAQ:CPXX) Jumped 71.59%: Westar Energy, Inc. (NYSE:WR), Medtronic plc ...KC RegisterCelator Pharmaceuticals, Inc. (NASDAQ:CPXX) said that, Jazz Pharmaceuticals Plc will buy U.S.-based Celator Pharmaceuticals Inc in a cash deal valued at about $1.5 billion, to gain access to an investigational product in development for treating acute ...Notable Mergers and Acquisitions 5/31: (GXP)/(WR) (JAZZ)/(CPXX) (SQI) (MKTO)StreetInsider.comUS stocks struggle as energy companies fall with oil pricesMyAJCall 201 news articles »
06/01/16 09:31 PMStock Earnings Review: Chesapeake Energy Corporation (NYSE:CHK), Celator Pharmaceuticals, Inc. (NASDAQ:CPXX) - Beacon Chronicle - Beacon ChronicleStock Earnings Review: Chesapeake Energy Corporation (NYSE:CHK), Celator Pharmaceuticals, Inc. (NASDAQ:CPXX)Beacon ChronicleLast Trade: The Company closed its last session at $4.29 with the gain of 3.13%. The market capitalization of the company is $2.99 Billion, with the average Volume of 47.84 Million. The stock currently has its 52-Week High range of $14.27 and 52-week ...and more »
06/01/16 09:31 PMCelator Pharmaceuticals, Inc. (CPXX) Takes off on Takeover Bid - InvestorGuide - Smarter AnalystCelator Pharmaceuticals, Inc. (CPXX) Takes off on Takeover BidInvestorGuideShares of Ewing, New Jersey, based Celator Pharmaceuticals, Inc. (CPXX) rose on Tuesday, against the backdrop of a mixed day in stocks overall. Celetor's stock was up 71.59%, rising $12.55 per share, to close at $30.08, on volume of 38,250,460 shares.Home Buyout Celator Pharmaceuticals Inc. | $CPXX Stock | Jazz Pharmaceuticals To Buy Company...TickerTV News (press release)Analysts Downgrade Two Volatile Healthcare Stocks: Celator Pharmaceuticals Inc (CPXX), StemCells Inc (STEM)Smarter AnalystAnalysts Downgrades Report: Celator Pharmaceuticals Inc (NASDAQ:CPXX)CWRU ObserverInvestorplace.com -LearnBonds -The Cerbat Gemall 138 news articles »
06/01/16 03:59 PMCelator Pharmaceuticals, Inc. :CPXX-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
06/01/16 03:30 PMTrending Biotech Stocks Update: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , PDL BioPharma, Inc. (NASDAQ:PDLI) - Is stories - Trending Biotech Stocks Update: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , PDL BioPharma, Inc. (NASDAQ:PDLI)Is storiesCelator Pharmaceuticals Inc. (NASDAQ:CPXX) increased +71.59% to $30.08 while traded 38.25 million shares on 5/31/2016. The stock price negotiated for value between $29.82 to $30.10 in recent trading session. During the past 52 weeks, the stock's price ...and more »
06/01/16 03:30 PMCelator Pharmaceuticals (NASDAQ:CPXX) & DURECT Corporation (NASDAQ:DRRX) Healthcare Movers to Watch - Wall Street 24 - Celator Pharmaceuticals (NASDAQ:CPXX) & DURECT Corporation (NASDAQ:DRRX) Healthcare Movers to WatchWall Street 24On Tuesday, Shares of Celator Pharmaceuticals Inc (NASDAQ:CPXX) gained 71.59% to $30.08. The share price is trading in a range of $29.82 – $30.10. The stock exchanged hands with 38.25 Million shares contrast to its average daily volume of 3.20 Million ...and more »
06/01/16 03:30 PMActive Stocks' Revenge with Bears- BioMarin Pharmaceutical (NASDAQ:BMRN), Celator Pharmaceuticals (CPXX ... - Seneca Globe - Active Stocks' Revenge with Bears- BioMarin Pharmaceutical (NASDAQ:BMRN), Celator Pharmaceuticals (CPXX ...Seneca GlobeBioMarin Pharmaceutical Inc. (NASDAQ:BMRN) tries to make charm in street, as shares traded at $89.65 with inches up of 0.63% in last trading session. BioMarin (BMRN) withdraws market authorization application for Kyndrisa (drisapersen) in Europe.and more »
06/01/16 11:02 AMCelator Pharmaceuticals Inc. (NASDAQ:CPXX) Quarterly EPS Estimate At $-0.17 - Investor Newswire - Celator Pharmaceuticals Inc. (NASDAQ:CPXX) Quarterly EPS Estimate At $-0.17Investor NewswireFirst Call stated that Celator Pharmaceuticals Inc. (NASDAQ:CPXX) can touch $22.05 in coming one year. For the next quarter, the per-share earnings target is $-0.17 and for ongoing fiscal at $-0.62. EPS target for next year is $-0.05 versus the mean ...and more »
06/01/16 11:02 AMAnalyst's Checklist Stocks: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , Astrazeneca PLC (NYSE:AZN) - Street Updates - Analyst's Checklist Stocks: Celator Pharmaceuticals Inc. (NASDAQ:CPXX) , Astrazeneca PLC (NYSE:AZN)Street UpdatesOn 5/31/2016, Celator Pharmaceuticals Inc. (NASDAQ:CPXX) ended trading session higher at $30.08 with +71.59%. The company traded a volume of 38.25 million shares as comparison to average volume of 4.54 million shares. During the 52 –week period, ...
06/01/16 11:02 AMStock Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Cancels Analyst and Investor Meeting and Postpones ... - Smarter Analyst - Smarter AnalystStock Update (NASDAQ:CPXX): Celator Pharmaceuticals Inc Cancels Analyst and Investor Meeting and Postpones ...Smarter AnalystCelator Pharmaceuticals Inc (NASDAQ:CPXX) announced that it is cancelling its Analyst and Investor meeting scheduled for Saturday, June 4, 2016 at 7:00 p.m. CT and that the company's board of directors has postponed its annual meeting of stockholders, ...
06/01/16 10:18 AMCELATOR PHARMACEUTICALS, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout - [Business Wire] - Rigrodsky & Long, P.A.:
06/01/16 09:55 AMCPXX: Jazz Acquires Celator for $30.25 per Share -
05/31/16 03:28 PMStocks Buzz - Cliffs Natural Resources, (NYSE:CLF), Celator Pharmaceuticals, (NASDAQ:CPXX) - Wall Street 24 - Stocks Buzz - Cliffs Natural Resources, (NYSE:CLF), Celator Pharmaceuticals, (NASDAQ:CPXX)Wall Street 24On Friday, Shares of Cliffs Natural Resources Inc. (NYSE:CLF) gained 10.10% to $3.07. CLF, as of current trade, has shown weekly upbeat performance of 5.14 percent which was maintained at -43.04 percent in 1-month period. The shares of Cliffs Natural ...and more »
05/31/16 03:01 PMCelator Pharmaceuticals® Cancels Analyst and Investor Meeting and Postpones Annual Meeting of Stockholders - [PR Newswire] - EWING, N.J., May 31, 2016 /PRNewswire/ -- Celator Pharmaceuticals, Inc. (CPXX) today announced that it is cancelling its Analyst and Investor meeting scheduled for Saturday, June 4, 2016 at 7:00 p.m. CT and that the company's board of directors has postponed its annual meeting of stockholders, previously scheduled for June 8, 2016. Data from the Phase 3 clinical trial of VYXEOS™ is still scheduled to be presented at the ASCO Annual Meeting in Chicago on June 4, 2016 and at the European Hematology Association (EHA) Annual Congress in Copenhagen on June 11, 2016. The ASCO abstracts became available at 5:00 p.m. ET on May 18, 2016 (abstracts.asco.org) and the EHA abstracts became available at 12:00 p.m. CET on May 19, 2016 (EHA Learning Center - Official eLearning Portal of the European Hematology Association).
05/31/16 11:36 AMIs 70% an Excessive Premium for Celator Pharmaceuticals Inc? (CPXX JAZZ) - InvestorPlaceInvestorPlace - Stock Market News, Stock Advice & Trading Tips Jazz Pharmaceuticals stock is hovering around breakeven after agreeing to acquire Celator (CPXX) for a 73% premium. Does the deal make sense? The post Is 70% an Excessive Premium for Celator Pharmaceuticals Inc? (CPXX JAZZ) appeared first on InvestorPlace.
05/31/16 10:34 AMInvestor's Healthcare Focused Stocks: Pfizer, Inc. (NYSE:PFE) , Celator Pharmaceuticals Inc. (NASDAQ:CPXX) - Is stories - Is storiesInvestor's Healthcare Focused Stocks: Pfizer, Inc. (NYSE:PFE) , Celator Pharmaceuticals Inc. (NASDAQ:CPXX)Is storiesIn most recently trading session on 5/27/2016, Celator Pharmaceuticals Inc. (NASDAQ:CPXX) climbed +0.17% while traded on 1.15 million shares versus it's an average volume of 4 million shares. The company recorded the last trade with the price of $17.53.and more »
05/31/16 10:34 AMCelator Pharmaceuticals Inc Cliffs Natural Resources Inc (CLF) Intercept Pharmaceuticals Inc (ICPT) And Micron ... - TCC - TCCCelator Pharmaceuticals Inc Cliffs Natural Resources Inc (CLF) Intercept Pharmaceuticals Inc (ICPT) And Micron ...TCCCelator Pharmaceuticals Inc. (NASDAQ:CPXX), Cliffs Natural Resources Inc. (NYSE:CLF), Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), and Micron Technology Inc. (NASDAQ:MU) have been among the top premarket gainers today. The Country Caller ...Stocks Buzz - Cliffs Natural Resources, (NYSE:CLF), Celator Pharmaceuticals, (NASDAQ:CPXX)Wall Street 24Analyst Upgrades: Cliffs Natural Resources Inc, Intercept Pharmaceuticals Inc, and Jazz Pharmaceuticals plcSchaeffers Research (blog)all 40 news articles »
05/31/16 10:34 AMHome Buyout Celator Pharmaceuticals Inc. | $CPXX Stock | Jazz Pharmaceuticals To Buy Company... - TickerTV News (press release) - TickerTV News (press release)Home Buyout Celator Pharmaceuticals Inc. | $CPXX Stock | Jazz Pharmaceuticals To Buy Company...TickerTV News (press release)On Tuesday morning before the market opened, Jazz Pharmaceuticals announced that they will buy Celator Pharmaceuticals for roughly $1.5 billion or $30.25 per share after shares closed on Friday at $17.53, a 73% jump in value. This should add excellent ...Jazz Pharma (JAZZ) Confirms Agreement to Acquire Celator Pharma (CPXX) for $30.25/Share, or ~$1.5BStreetInsider.comTuesday Morning's Market Insights: Celator Pharmaceuticals Inc (CPXX), Intercept Pharmaceuticals Inc (ICPT), Amicus ...Smarter AnalystCelator Pharmaceuticals Inc. (CPXX) Has Soared To A New High After MergerRTT NewsThe Cerbat Gem -Wall Street 24 -Wall Street Journalall 61 news articles »
About Celator Pharmaceuticals

Celator Pharmaceuticals logoCelator Pharmaceuticals, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in developing products to improve patient outcomes in cancer. The Company's technology platform, CombiPlex, enables the design and evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver anti-cancer activity. The Company's product, VYXEOS, a nano-scale liposomal formulation of cytarabine:daunorubicin, in Phase III clinical testing for the treatment of acute myeloid leukemia. The Company also conducted clinical development efforts on CPX-1, a nano-scale liposomal formulation of irinotecan:floxuridine for the treatment of colorectal cancer; and has a preclinical stage product candidate CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation. The Company operates in the United States and Canada.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CPXX
  • CUSIP:
Key Metrics:
  • Previous Close: $30.19
  • 50 Day Moving Average: $22.98
  • 200 Day Moving Average: $9.98
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $1.28B
  • Current Quarter EPS Consensus Estimate: $-0.62 EPS
Additional Links:
Celator Pharmaceuticals (NASDAQ:CPXX) Chart for Friday, June, 24, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha